Loading...
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer’s disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies. An additional phase III trial is ongoing...
Na minha lista:
| Udgivet i: | J Neuroinflammation |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265363/ https://ncbi.nlm.nih.gov/pubmed/25476011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-014-0198-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|